IDiyas

For the Inventor, By the Inventor

Hyderabad Telangana, India

Venkata Sunil Kumar Indukuri

USPTO Granted Patents = 26 

 

Average Co-Inventor Count = 5.4

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Kukatpally, IN (2012)
  • Hyderabad, IN (2013 - 2022)

Company Filing History:

goldMedal26 out of 64 
 
Laurus Labs Private Limited
 patents

Years Active: 2012-2022

Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents
1. 11427570 - Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof (2022-08-30),
2. 11299477 - Process for the preparation of Pazopanib or a pharmaceutically acceptable salt thereof (2022-04-12),
3. 11066368 - Process for the preparation and particle size reduction of pirfenidone (2021-07-20),
4. 11040961 - Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof (2021-06-22),
5. 10836753 - Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof (2020-11-17),
6. 10800809 - Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof (2020-10-13),
7. 10738038 - Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof (2020-08-11),
8. 10730859 - Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof (2020-08-04),
9. 10669264 - Process for the preparation of macitentan (2020-06-02),
10. 10654872 - Polymorphs of dolutegravir and salts thereof (2020-05-19),
11. 10647729 - Polymorphs of dolutegravir and salts thereof (2020-05-12),
12. 10626091 - Process for the preparation of enzalutamide (2020-04-21),
13. 10597404 - Polymorphs of dolutegravir and salts thereof (2020-03-24),
14. 10428053 - Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof (2019-10-01),
15. 10364269 - Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof (2019-07-30),

Title: Venkata Sunil Kumar Indukuri: Innovator in Pharmaceutical Processes

Introduction

Venkata Sunil Kumar Indukuri is an accomplished inventor based in Hyderabad, Telangana, India. With a remarkable record of 26 patents to his name, he has made significant contributions to the field of pharmaceuticals, particularly in the development and preparation of complex compounds.

Latest Patents

One of his most recent innovations is the "Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof." This invention pertains to an improved method for synthesizing pazopanib, as well as novel polymorphic forms of pazopanib hydrochloride and its intermediates. This advancement is noteworthy as pazopanib is a key therapeutic agent in the treatment of various cancers.

Career Highlights

Venkata currently works at Laurus Labs Private Limited, a leading pharmaceutical company known for its commitment to quality and innovation. His work at Laurus Labs has allowed him to leverage his expertise in creating processes that improve the yield and efficiency of drug production, enhancing the potential for making life-saving medications more accessible.

Collaborations

Throughout his career, Venkata has collaborated with notable coworkers such as Satyanarayana Chava and Ram Thaimattam. These partnerships have fostered a creative environment that encourages the sharing of ideas and innovative solutions, further driving advancements in pharmaceutical sciences.

Conclusion

Venkata Sunil Kumar Indukuri exemplifies the spirit of innovation within the pharmaceutical industry. With his extensive portfolio of patents and ongoing contributions at Laurus Labs Private Limited, he continues to pave the way for new developments that could significantly impact patient care and treatment options in the future. His work not only demonstrates his commitment to science but also underscores the vital role of inventors in shaping the landscape of modern healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…